Q-omics provides the consensus-scored ASNSD1 profile across patient tissues and cancer cell-line models. ASNSD1 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, ASNSD1 is differentially expressed in 11, with the highest sampling consensus in HNSC. Additionally, ASNSD1 RNA expression shows 20,223 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRP, HNSC, and ACC as cancer lineages where ASNSD1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ASNSD1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ASNSD1 survival associations across molecular data types. ASNSD1 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (7) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ASNSD1 RNA expression–survival associations across cancer types. High ASNSD1 expression shows unfavorable associations in KIRP, LIHC, ACC and SCLC, but favorable associations in KIRC and LUAD. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for ASNSD1 RNA expression.
This table summarizes ASNSD1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 3. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for ASNSD1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ASNSD1 shows lower tumor expression in KICH and THCA and higher tumor expression in HNSC, LIHC, COAD and CHOL. The HNSC box plot shows higher ASNSD1 RNA expression in tumor versus normal tissue (log2 FC = +0.467, t-test p < 0.001).
This table shows molecular features associated with ASNSD1 in patient tissues and cancer cell lines. In patient samples, ASNSD1 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, ASNSD1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in OVARY and UPPER_AERODIGESTIVE_TRACT.
